Lucitanib strongly inhibits FGFR1, FGFR2, and VEGFR1–3, and it has antiangiogenic and broad‐spectrum antitumor activity against several cancers, including small cell lung cancer, breast cancer, nasopharyngeal carcinoma, colorectal cancer, ovarian cancer, and kidney cancer.336, 337. This evidence concerns the gene FGFR2 and breast carcinoma.